230 related articles for article (PubMed ID: 29346342)
1. Attention-Deficit/Hyperactivity Disorder Medication Prescription Claims Among Privately Insured Women Aged 15-44 Years - United States, 2003-2015.
Anderson KN; Ailes EC; Danielson M; Lind JN; Farr SL; Broussard CS; Tinker SC
MMWR Morb Mortal Wkly Rep; 2018 Jan; 67(2):66-70. PubMed ID: 29346342
[TBL] [Abstract][Full Text] [Related]
2. Antidepressant Prescription Claims Among Reproductive-Aged Women With Private Employer-Sponsored Insurance - United States 2008-2013.
Dawson AL; Ailes EC; Gilboa SM; Simeone RM; Lind JN; Farr SL; Broussard CS; Reefhuis J; Carrino G; Biermann J; Honein MA
MMWR Morb Mortal Wkly Rep; 2016 Jan; 65(3):41-6. PubMed ID: 26821271
[TBL] [Abstract][Full Text] [Related]
3. Vital Signs: National and State-Specific Patterns of Attention Deficit/Hyperactivity Disorder Treatment Among Insured Children Aged 2-5 Years - United States, 2008-2014.
Visser SN; Danielson ML; Wolraich ML; Fox MH; Grosse SD; Valle LA; Holbrook JR; Claussen AH; Peacock G
MMWR Morb Mortal Wkly Rep; 2016 May; 65(17):443-50. PubMed ID: 27149047
[TBL] [Abstract][Full Text] [Related]
4. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
[TBL] [Abstract][Full Text] [Related]
5. Patient and provider characteristics related with prescribing of ADHD medication: Nationwide health insurance claims database study in Korea.
Song I; Lee MS; Lee EK; Shin JY
Asia Pac Psychiatry; 2018 Mar; 10(1):. PubMed ID: 28631372
[TBL] [Abstract][Full Text] [Related]
6. Prescription Stimulant Use During Pregnancy and Risk of Neurodevelopmental Disorders in Children.
Suarez EA; Bateman BT; Hernandez-Diaz S; Straub L; McDougle CJ; Wisner KL; Gray KJ; Pennell PB; Lester B; Zhu Y; Mogun H; Huybrechts KF
JAMA Psychiatry; 2024 May; 81(5):477-488. PubMed ID: 38265792
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity Disorder.
Sultan RS; Wang S; Crystal S; Olfson M
JAMA Netw Open; 2019 Jul; 2(7):e197850. PubMed ID: 31348506
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
Molife C; Bernauer MJ; Farr AM; Haynes VS; Kelsey D
Postgrad Med; 2012 Sep; 124(5):7-22. PubMed ID: 23095422
[TBL] [Abstract][Full Text] [Related]
9. [Methylphenidate prescriptions in the city of Cologne: overrepresentation of privately insured patients. Results of an analysis based on prescription data].
Bessou H; Zeeb H; Puteanus U
Gesundheitswesen; 2007 May; 69(5):292-6. PubMed ID: 17582546
[TBL] [Abstract][Full Text] [Related]
10. Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder.
Aldridge AP; Kroutil LA; Cowell AJ; Reeves DB; Van Brunt DL
Pharmacoeconomics; 2011 Jul; 29(7):621-35. PubMed ID: 21473655
[TBL] [Abstract][Full Text] [Related]
11. Adult ADHD: prevalence of diagnosis in a US population with employer health insurance.
Montejano L; Sasané R; Hodgkins P; Russo L; Huse D
Curr Med Res Opin; 2011; 27 Suppl 2():5-11. PubMed ID: 21973227
[TBL] [Abstract][Full Text] [Related]
12. Psychosis with Methylphenidate or Amphetamine in Patients with ADHD.
Moran LV; Ongur D; Hsu J; Castro VM; Perlis RH; Schneeweiss S
N Engl J Med; 2019 Mar; 380(12):1128-1138. PubMed ID: 30893533
[TBL] [Abstract][Full Text] [Related]
13. Overlapping Prescriptions of Stimulants for Children and Adolescents With Attention-Deficit Hyperactivity Disorder.
Chen CY; Yeh HH; Fang SY; Wu EC; Chang IS; Lin KM
Psychiatr Serv; 2012 Oct; 63(10):1011-8. PubMed ID: 22911441
[TBL] [Abstract][Full Text] [Related]
14. Attention-Deficit/Hyperactivity Disorder Medication and Unintentional Injuries in Children and Adolescents.
Ghirardi L; Larsson H; Chang Z; Chen Q; Quinn PD; Hur K; Gibbons RD; D'Onofrio BM
J Am Acad Child Adolesc Psychiatry; 2020 Aug; 59(8):944-951. PubMed ID: 31302218
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and determinants of attention deficit/hyperactivity disorder (ADHD) medication use during pregnancy: Results from the Quebec Pregnancy/Children Cohort.
Lemelin M; Boukhris T; Zhao JP; Sheehy O; Bérard A
Pharmacol Res Perspect; 2021 May; 9(3):e00781. PubMed ID: 34003597
[TBL] [Abstract][Full Text] [Related]
16. Trends in medication treatment for ADHD.
Castle L; Aubert RE; Verbrugge RR; Khalid M; Epstein RS
J Atten Disord; 2007 May; 10(4):335-42. PubMed ID: 17449832
[TBL] [Abstract][Full Text] [Related]
17. Attention Deficit Hyperactivity Disorder Medication Use Among Teens and Young Adults.
Johansen ME; Matic K; McAlearney AS
J Adolesc Health; 2015 Aug; 57(2):192-7. PubMed ID: 26026476
[TBL] [Abstract][Full Text] [Related]
18. Association between medication prescription for atopic diseases and attention-deficit/hyperactivity disorder.
van der Schans J; Pleiter JC; de Vries TW; Schuiling-Veninga CC; Bos JH; Hoekstra PJ; Hak E
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):186-91. PubMed ID: 27315741
[TBL] [Abstract][Full Text] [Related]
19. Management of newer medications for attention-deficit/hyperactivity disorder in commercial health plans.
Hodgkin D; Horgan CM; Quinn AE; Merrick EL; Stewart MT; Leslie LK
Clin Ther; 2014 Dec; 36(12):2034-2046. PubMed ID: 25450473
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.
Christensen L; Sasané R; Hodgkins P; Harley C; Tetali S
Curr Med Res Opin; 2010 Apr; 26(4):977-89. PubMed ID: 20178404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
